Tumor necrosis factor (TNF-α) (TNF-α)

Tumor necrosis factor (TNF), specifically the alpha isoform (TNF-α), is a potent pleiotropic pro-inflammatory cytokine primarily produced by activated macrophages, T cells, and natural killer cells (UniProt P01375). It plays a central role in the innate and adaptive immune response by signaling through two distinct receptors, TNFR1 and TNFR2, to regulate processes such as cell death, survival, and inflammation (PubMed PMC2909729). Dysregulation and overproduction of TNF-α are implicated in the pathogenesis of numerous chronic inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (StatPearls - TNF-alpha Inhibitors). As a result, the TNF pathway has become a cornerstone of modern biopharmaceutical intervention, with several blockbuster drugs developed to modulate its activity (NIH - National Library of Medicine). These therapeutic agents, including monoclonal antibodies and soluble receptor fusion proteins, work by binding and neutralizing TNF-α before it can interact with its cell-surface receptors (DrugBank). Clinical use of these inhibitors has revolutionized the treatment of systemic inflammatory diseases, significantly improving patient outcomes and quality of life (PubMed PMC6128255). However, because TNF-α is vital for host defense, its inhibition is associated with serious safety concerns, such as the reactivation of latent tuberculosis and an increased risk of opportunistic infections (FDA Boxed Warning).

Other names

Tumor necrosis factor alphaTNFATNFSF2CachectinTumor necrosis factor ligand superfamily member 2

Neutralization of soluble and membrane-bound TNF-α to prevent binding to TNFR1 and TNFR2 receptors, thereby inhibiting downstream pro-inflammatory signaling cascades (PubMed PMC2909729).